fig1

Urothelial bladder cancer progression: lessons learned from the bench

Figure 1. Representative images of immunohistochemical positive reactions for CD31, D2-40, p-mTOR, RKIP, CD147, MCT1, MCT4 in non-muscle invasive (c) and muscle invasive (a, b, d-g) urothelial bladder carcinoma (original magnifications indicated). (a) An embolus of malignant cells intravased in an intratumoral blood vessel highlighted by CD31 (×400); (b) isolated malignant cells (*) and malignant embolus (†) invading intratumoral lymphatic vessels highlighted by D2-40 (×200); (c) heterogeneous pattern of p-mTOR immunoexpression, with the intensity of staining of staining being lost from the luminal to the basal cell layers of the urothelium (×100); (d) heterogeneous pattern of RKIP immunoexpression, with the tumor core being more intensely stained than the invasive front (×100); (e) strong CD147 membrane immunoexpression in the inner layers of the tumor (×100); (f) immunoexpression of MCT1 in the malignant urothelium (×200); (g) immunoexpression of MCT4 in the malignant urothelium (×200). MCT: Monocarboxylate transporter; p-mTOR: Phospho-mammalian target of rapamycin; RKIP: Raf kinase inhibitor protein

Journal of Cancer Metastasis and Treatment
ISSN 2454-2857 (Online) 2394-4722 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/